The Gateway Pundit previously reported that COVID cases are plummeting in India thanks to new rules that promote Ivermectin and hydroxychloroquine to its massive population.
The 33 districts in Uttar Pradesh, India have now become free from COVID-19 government informed on Friday. The recovery rate has increased up to 98.7% proving the effectiveness of IVERMECTIN as part of the “Uttar Pradesh Covid Control Model.”
This state has an estimated population of 241 million people in 2021 and has the highest population in India. This is almost two-thirds of the United States population in 2021 and yet it is now a COVID-19 free nation.
So what could the United States be doing wrong? Let’s ask Dr. Fauci.
Hindustan Times reported on this big development:
Overall, the state has a total of 199 active cases, while the positivity rate came down to less than 0.01 per cent. The recovery rate, meanwhile, has improved to 98.7 per cent. As per the state’s health bulletin, Uttar Pradesh reported only 11 new Covid-19 cases and zero deaths in the last 24 hours.
India Today also reported on this last August 31:
The active caseload in Uttar Pradesh is down to 269, while the percentage of active cases against the total confirmed cases is 0 per cent. The active caseload, which was at a high of 3,10,783 in April, has reduced by over 99 per cent. Fresh Covid-19 cases in the state have remained below 100 for 50 consecutive days. Of the 1,87,638 samples tested in the last 24 hours, 21 tested positive. In the same period, another 17 patients recovered from the infection, adding to the recovery of over 16,86,182 people so far. (These numbers are in lakh so the comma placement is different in the US. 1,87,638 lakh is 187,638)
Uttar Pradesh is the leading state in India to use Ivermectin as early and preventatively in all family contacts. And this state is one of the five lowest COVID cases of all states in India despite having only a low vaccination rate of 5.8% fully vaccinated compared to the USA that has 54% fully vaccinated.
The USA has 179,289,983 fully vaccinated as of September 14 while Uttar Pradesh has 15,236,150 who got their second dose.
Here’s a little background on the use of Ivermectin in UP, The Indian Express reported:
“Uttar Pradesh was the first state in the country to introduce large-scale prophylactic and therapeutic use of Ivermectin. In May-June 2020, a team at Agra, led by Dr. Anshul Pareek, administered Ivermectin to all RRT team members in the district on an experimental basis. It was observed that none of them developed Covid-19 despite being in daily contact with patients who had tested positive for the virus,” Uttar Pradesh State Surveillance Officer Vikssendu Agrawal said.
He added that based on the findings from Agra, the state government sanctioned the use of Ivermectin as a prophylactic for all the contacts of Covid patients and later cleared the administration of therapeutic doses for the treatment of such patients.
Claiming that timely introduction of Ivermectin since the first wave has helped the state maintain a relatively low positivity rate despite its high population density, he said, “Despite being the state with the largest population base and a high population density, we have maintained a relatively low positivity rate and cases per million of population”.
He said that apart from aggressive contact tracing and surveillance, the lower positivity and fatality rates may be attributed to the large-scale use of Ivermectin use in the state, adding that the drug has recently been introduced in the National Protocol for Covid treatment and management. “Once the second wave subsides, we would conduct our own study as there has been an emerging body of evidence to substantiate our timely use of Ivermectin from the first wave itself,” Vikasendu told The Indian Express.”
Last August, the government of UP issued a notification to have Ivermectin (12 mg) tablets. The Dialogue reported:
“The government notification reads, “Doctors are advising to take ivermectin 12 mg to contain the impact of pandemic. This medicine is quite effective in protecting from covid-19. Therefore, we appeal each and every citizen to have this tablet.” The notification then goes on to explain the dosage: For positive patients isolated at home (one tablet per day for three days and for primary and secondary contacts (one tablet each on the first and 7th day).”
Both Uttar Pradesh and Delhi have seen an incredible drop in COVID-19 cases because they use Ivermectin early and preventatively. Whereas Kerala, a tiny state located in southern India that is over-dependent on vaccines and less dependent on Ivermectin, has been reporting a significant increase in COVID-19 cases. Keep in mind that Uttar Pradesh has eight times larger population than Kerala.
More information on Kerala’s COVID- 19 cases on The Desert Review:
“While Kerala included Ivermectin in their state’s guideline in April, they restricted it’s use to only in Class B – severe cases or those with associated disease, making its use much less than if mild cases were allowed. This meant it was reserved as a late treatment if used at all.
Finally, Kerala abandoned Ivermectin use altogether on August 5, 2021.
Juan Chamie, the Cambridge-based data analyst who has provided graphical insight and published on COVID, provided his answer to why Kerala’s COVID cases have spun out of control.
“My main current explanation is the lack of early treatment. Kerala’s COVID protocol from April 2021 included Ivermectin, but not as an early treatment. As a result, only a small group qualified, those in Category B patients having high-risk factors. The new protocol from August 5 is even worse. They removed Ivermectin (completely).”
Despite a widespread attempt by the media and WHO to convince the world that India has dropped Ivermectin by citing the DGHS, the ICMR and AIIMS have not changed their position, and Ivermectin remains in the India National Protocol.”
Of course, the WHO, pharmaceutical companies, fake news media, and Fauci are not happy with this big development. New York Times will have a meltdown with this news.
SOURCE: The Gateway Pundit
Commenti